Immune-based therapies for hepatocellular carcinoma

被引：181

作者：

Pinato, David J. ^{[1
]}

Guerra, Nadia ^{[2
]}

Fessas, Petros ^{[1
]}

Murphy, Ravindhi ^{[1
]}

Mineo, Takashi ^{[3
]}

Mauri, Francesco A. ^{[1
]}

Mukherjee, Sujit K. ^{[4
]}

Thursz, Mark ^{[4
]}

Wong, Ching Ngar ^{[1
]}

Sharma, Rohini ^{[1
]}

Rimassa, Lorenza ^{[5
,6
]}

机构：

[1] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London W12 0HS, England

[2] Imperial Coll London, Dept Life Sci, South Kensington Campus,Exhibit Rd, London SW7 2AZ, England

[3] Tokyo Med & Dent Univ, Tokyo, Japan

[4] Imperial Coll London, Dept Metab Digest & Reprod, St Marys Hosp, Praed St, London, England

[5] Humanitas Clin & Res Ctr IRCCS, Med Oncol & Haematol Unit, Humanitas Canc Ctr, Via Manzoni 56, I-20089 Milan, Italy

[6] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini, I-20090 Milan, Italy

来源：

ONCOGENE | 2020年 / 39卷 / 18期

基金：

英国惠康基金;

关键词：

REGULATORY T-CELLS; GROWTH-FACTOR-BETA; CHRONIC HEPATITIS-B; SUPPRESSOR-CELLS; DENDRITIC CELLS; TUMOR MICROENVIRONMENT; DOUBLE-BLIND; PHASE-III; TGF-BETA; ADOPTIVE IMMUNOTHERAPY;

D O I：

10.1038/s41388-020-1249-9

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.

引用

页码：3620 / 3637

页数：18

共 50 条

[21] Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma
Samimi, Mahtab
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (03) : 391 - 407
[22] Dendritic cells and immune-based therapies
Steinman, RM
EXPERIMENTAL HEMATOLOGY, 1996, 24 (08) : 859 - 862
[23] Immune-based therapies in penile cancer
Vidhu B. Joshi
Philippe E. Spiess
Andrea Necchi
Curtis A. Pettaway
Jad Chahoud
Nature Reviews Urology, 2022, 19 : 457 - 474
[24] Immune-based therapies and HIV infection
Weiss, L
ANNALES DE MEDECINE INTERNE, 2002, 153 (04): : 227 - 236
[25] Immune-based therapies in the management of multiple myeloma
Saurabh Zanwar
Bharat Nandakumar
Shaji Kumar
Blood Cancer Journal, 10
[26] Immune-based therapies in the management of multiple myeloma
Zanwar, Saurabh
Nandakumar, Bharat
Kumar, Shaji
BLOOD CANCER JOURNAL, 2020, 10 (08)
[27] Immune-based therapies for treatment of HIV infection
Piscitelli, SC
Minor, JR
Saville, MW
Davey, RT
ANNALS OF PHARMACOTHERAPY, 1996, 30 (01) : 62 - 76
[28] Emerging Targeted and Immune-Based Therapies in Sarcoma
Pollack, Seth M.
Ingham, Matthew
Spraker, Matthew B.
Schwartz, Gary K.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (02) : 125 - +
[29] Epigenetics of melanoma: implications for immune-based therapies
Fratta, Elisabetta
Sigalotti, Luca
Covre, Alessia
Parisi, Giulia
Coral, Sandra
Maio, Michele
IMMUNOTHERAPY, 2013, 5 (10) : 1103 - 1116
[30] Dendritic cells in transplantation and immune-based therapies
Young, James W.
Merad, Miriam
Hart, Derek N. J.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (01) : 23 - 32

← 1 2 3 4 5 →